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Venous thromboembolism (VTE) is a significant clinical and public health concern. We eval-
uated a variety of multilevel factors—demographics, clinical and insurance status, preexist-
ing comorbid conditions, and hospital characteristics—for VTE diagnosis among
hospitalizations of US adults.
Methods
We generated adjusted odds ratios with 95% confidence intervals (CIs) and determined
sources of outcome variation by conducting multilevel logistic regression analysis of data
from the 2011 Nationwide Inpatient Sample that included 6,710,066 hospitalizations of US
adults nested within 1,039 hospitals.
Results
Among hospitalizations of adults, age, sex, race or ethnicity, total days of hospital stay, sta-
tus of health insurance, and operating room procedure were important determinants of VTE
diagnosis; each of the following preexisting comorbid conditions—acquired immune defi-
ciency syndrome, anemia, arthritis, congestive heart failure, coagulopathy, hypertension,
lymphoma, metastatic cancer, other neurological disorders, obesity, paralysis, pulmonary
circulation disorders, renal failure, solid tumor without metastasis, and weight loss—was as-
sociated independently with 1.04 (95% CI: 1.02−1.06) to 2.91 (95% CI: 2.81−3.00) times in-
creased likelihood of VTE diagnosis than among hospitalizations of adults without any of
these corresponding conditions. The presence of 2 or more of such conditions was associ-
ated a 180%−450% increased likelihood of a VTE diagnosis. Hospitalizations of adults who
were treated in urban hospitals were associated with a 14%−15% increased likelihood of
having a VTE diagnosis than those treated in rural hospitals. Approximately 7.4% of the
total variation in VTE diagnosis occurred between hospitals.
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Conclusion
The presence of certain comorbidities and hospital contextual factors is associated with sig-
nificantly elevated likelihood of VTE diagnosis among hospitalizations of adults. The find-
ings of this study underscore the importance of clinical risk assessment and adherence to
evidence-based clinical practice guidelines in preventing VTE, as well as the need to evalu-
ate potential contextual factors that might modify the risk of VTE among
hospitalized patients.
Introduction
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary
embolism (PE), is a serious clinical and public health concern [1, 2]. VTE not only imposes a
substantial socioeconomic burden on healthcare systems, but also is responsible for numerous
debilitating health consequences, including morbidity, mortality, disability, and diminished
health-related quality of life among affected individuals [1–3]. In the United States, based on
the analyses of hospital discharge data for the years 2009−2010, diagnoses of VTE were re-
corded in as many as 770,000 hospitalizations of adults annually [4, 5]. Studies also have found
that more than 70% of patients who experienced VTE events had VTE identified in a commu-
nity or outpatient setting, and at least 30% of these outpatients with VTE had been hospitalized
during the previous 3 months [6, 7]. While the classic Virchow’s triad describes vascular endo-
thelial damage, stasis of blood flow, and hypercoagulability of blood as the three general com-
ponents for the pathogenesis of venous thrombosis, advances in research have further
identified many specific demographic (e.g., advanced age), biological (e.g., increased levels of
prothrombin and fibrinogen), behavioral (e.g., smoking), environmental (e.g., long-distance
travel), and health conditions-related risk factors (e.g., surgical and comorbid conditions) that
show a simultaneous presence or a sequential interplay of transient and persistent risk factors
in the development of VTE [8–10].
As an important health condition that potentially is preventable through implementation of
thrombosis risk assessment and evidence-based clinical practice guidelines, VTE is especially a
concern for hospitalized patients [11–13]. Previous studies have suggested hospital characteris-
tics (e.g., hospital size, ownership, and teaching status) might influence health outcomes (e.g.,
short-term mortality and complications) among hospitalized patients [14, 15]. Currently, there
is considerable interest among health care providers, researchers, and public health profession-
als to identify individual- and group-level risk factors for VTE, to discern “compositional ef-
fects” (e.g., effects of patient characteristics) and “contextual effects” (e.g., effects of socio-
environmental or neighborhood characteristics) and to determine sources of variation (e.g.,
within group and between group) in VTE risk [11, 16, 17]. Such evidence is essential to identify
accurately patients who might benefit from VTE prophylaxis and to inform prevention strate-
gies for optimal care. Therefore, to strengthen the epidemiologic evidence and to fill the knowl-
edge gap in this largely unexplored area of research, we evaluated multilevel determinants,
comprising demographics, clinical and insurance status, preexisting comorbid conditions, and
hospital characteristics, of VTE diagnosis among hospitalizations of US adults by analyzing
data from the 2011 Nationwide Inpatient Sample (NIS).
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Methods
Ethics Statement
All procedures involving human participants and confidentiality were reviewed and approved
by the Research Ethics Review Board of the Agency for Healthcare Research and Quality
(AHRQ). Patient records for the NIS were anonymized and de-identified prior to public release
for analysis. Analysis of deidentified data from the NIS is exempt from federal regulations for
the protection of human research participants.
Data Source
The NIS is part of the Healthcare Cost and Utilization Project sponsored by the AHRQ [18]. It is
the largest all-payer inpatient care public database in the United States, with data on 5−8 million
annual unweighted hospitalizations of patients covered by Medicare, Medicaid, or private insur-
ance, and the uninsured from about 1,000 community hospitals. The NIS sampling frame com-
prises non-federal, short-term, general and specialty hospitals, and long-term acute care facilities.
Excluded from the NIS are short-term rehabilitation hospitals, long-term non-acute care hospi-
tals, psychiatric hospitals, and alcoholism or chemical dependency treatment facilities. The NIS
is designed to approximate a 20% stratified sample of U.S. community hospitals that include all
hospitalizations in the sampled hospitals [18]. The 2011 inpatient core file contained data for
8,023,590 hospitalizations drawn from 1,049 hospitals in participating states that make up 97% of
the population in the United States [19]. Details about the sampling methodology are described
elsewhere [18]. We restricted our analysis to a sample of hospitalizations for adults 18 years of age
and older (n = 6,834,910). After further excluding hospitalizations related to pregnancy, childbirth
and puerperium and those with missing information for the specific potential determinants we ex-
amined (patient age, sex, and total days of hospital stay; insurance status of primary expected
payer; and hospital bed size, location and teaching status, and ownership), a total of 6,710,066 hos-
pitalizations of adults nested within 1,039 hospitals were used as the analytical sample.
Outcome Variable
The NIS provides a maximum of 25 fields of diagnosis based on the International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) for each sampled hospitaliza-
tion. We determined VTE diagnosis by the presence of ICD-9-CM codes 415.1x, 451.1x, 451.2,
451.8x, 451.9, 453.2, 453.4x, 453.8x, and 453.9 in any of the 25 fields of diagnosis.
Multilevel Determinants of VTE Diagnosis
We assessed the potential determinants of VTE diagnosis at the levels of hospitalization and
hospitals. Those variables were selected for inclusion because they are well-known risk factors
for VTE or are relevant to VTE prevention.
Hospitalization level. We included demographics (i.e., age, sex, and race or ethnicity
−10.1% unstated), clinical and insurance status (i.e., total days of hospital stay, insurance status
of primary expected payer, and status of operating room procedure), and 29 preexisting co-
morbid conditions. The AHRQ 29-comorbidity index originally was developed in 1998 by Elix-
hauser and colleagues for risk adjustment in health outcome research using administrative data
[20]. Previous research has demonstrated that the index can predict accurately health outcomes
such as mortality for a general population and for hospitalizations of adults with a VTE diagno-
sis [4]. In the NIS, these 29 comorbidities are considered as coexisting medical conditions that
are not related directly to the principal diagnosis or the main reason for admission, and are
likely to have existed prior to the hospital stay [21]. Additionally, all ICD-9-CM procedure
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codes in the NIS are assigned to one of four broad categories of procedures—minor diagnostic,
minor therapeutic, major diagnostic, and major therapeutic—according to the AHRQ Proce-
dure Classes [22]. An operating room procedure was defined as having at least one major diag-
nostic or major therapeutic procedure during hospitalization [23].
Hospital level. We assessed the following hospital characteristics bed size (i.e., small, me-
dium, and large), location and teaching status (i.e., rural, urban non-teaching, urban teaching),
and ownership (i.e., “government, nonfederal,” “private, non-profit,” and “private, investor-
own”) as potential hospital-level determinants. Approximately one-third of the hospitals in a
given region, location, and teaching status combination were classified into categories of small,
medium, or large bed size by the NIS [19]. Because rural teaching hospitals were rare and ac-
counted for less than 2% of all hospitals, rural status within the category of “location and teach-
ing” was not classified further by teaching status in the NIS [19].
Statistical Analysis
We calculated the percentage distribution for and rate of VTE diagnosis among hospitalizations
of adults by age, sex, race or ethnicity, total days of hospital stay, insurance status of primary ex-
pected payer, and operating room procedure. We also estimated the number and percentage dis-
tributions of hospitals by bed size, location and teaching status, and ownership. Because the
outcome of interest (i.e., VTE diagnosis) was correlated among each group of hospitalizations of
adults who were treated within the same hospitals, we applied a multilevel modeling approach to
address clustered data in which analytical units (e.g., individual hospitalizations of adults) were
nested within other units of interest (e.g., hospitals) [16]. To evaluate the associations between
covariates and outcome (fixed effects) and to determine the variation in outcome (i.e., probabili-
ties of VTE diagnosis) between hospitals (random effects) while accounting for clustered data
structure, we specified four 2-level logistic regression models with fixed slopes and a random in-
tercept for each model [16]. More specifically, we constructed model 0, an unconditional empty
model with no covariate, to divulge the probabilities of VTE diagnosis between hospitals. Model
1 comprised demographic characteristics, clinical and insurance status (i.e., age, sex, race or eth-
nicity, total days of hospital stay, insurance status of primary expected payer, and operating room
procedure) as individual hospitalization level determinants (P< 0.05). Model 2 comprised all
model 1 determinants and significant preexisting comorbid conditions (P< 0.05). Model 3 com-
prised model 2 determinants and hospital level determinant (i.e., location and teaching status)
(P< 0.05). We employed a backward elimination procedure of stepwise regression to remove
any predictor with the highest P 0.05 for individual t-test of null hypothesis β = 0. We repeated
the same procedure until P< 0.05 for all predictors in models 1−3. The adjusted odds ratios
(aORs) with 95% confidence intervals (CIs) were generated to measure the strength of the associ-
ations. The intercept variance and intraclass correlation coefficient
ICC ¼ Intercept variance
Intercept variance þ residual variance

¼ s
2 ðvariance between hospitalsÞ
s2ðvariance between hospitalsÞþs2 ðvariance within hospitalsÞ

were calculated to assess between- and within-hospitals variation in VTE diagnosis.[24] We per-
formed weighted analyses to present nationally representative percentage estimates (i.e., frequen-
cy distribution and rate of VTE) using Complex Samples for Survey Analysis with SPSS 21 (IBM
Corp) and STATA 13 (StataCorp LP) to account for the complex sampling design. We conducted
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multilevel modeling using standard procedure for generalized linear mixed models with robust
variance estimation [16, 25].
Results
Characteristics of Hospitalizations and Hospitals
Table 1 shows that large percentages of all hospitalizations were of adults who were 50−79
years of ages (47.9%), were female (59.6%), were White (62.3%), had less than 7 total days of
hospital stay (81.2%), had Medicare as the primary expected payer (46.9%), and had no
Table 1. Percentage distribution and rate of VTE diagnosis among hospitalizations of US adults by demographic characteristics, clinical and in-
surance status, NIS, 2011.
Demographic characteristics, clinical and insurance status Sample distribution Rate of diagnosis of VTE
na %b CIc % CI P-Valued
Overall 6,710,066 100 − 2.4 2.4−2.5
Age (years) <0.001
18−49 2,305,943 34.3 33.5−35.2 1.5 1.4−1.5
50−79 3,210,405 47.9 47.3−48.4 2.9 2.8−3.0
 80 1,193,718 17.8 17.3−18.4 3.0 2.9−3.0
Sex <0.001
Male 2,708,723 40.4 39.9−40.9 2.9 2.8−2.9
Female 4,001,343 59.6 59.1−60.1 2.1 2.1−2.2
Race or ethnicitye <0.001
White 4,176,630 62.3 59.7−64.7 2.5 2.4−2.6
Black 929,079 13.9 12.6−15.3 2.7 2.6−2.9
Hispanic 641,244 9.6 8.2−11.3 1.7 1.5−1.8
Otherf 338,916 5.0 4.4−5.8 1.7 1.6−1.9
Not stated 624,197 9.2 7.1−11.8 2.5 2.3−2.7
Total days of hospital stay <0.001
< 7 days 5,453,256 81.2 80.7−81.7 1.7 1.6−1.7
 7 days 1,256,810 18.8 18.3−19.3 5.7 5.5−5.8
Primary expected payer <0.001
Medicare 3,142,530 46.9 45.9−47.8 2.9 2.8−3.0
Medicaid 1,003,379 15.0 14.1−15.9 1.6 1.5−1.7
Private including HMO 1,972,074 29.3 28.3−30.4 2.2 2.1−2.2
Self-pay or other payers 592,083 8.8 8.2−9.4 2.1 2.0−2.1
Operating room procedure <0.001
No procedure of any kind 2,404,657 36.0 34.9−37.1 2.7 2.6−2.8
Non-operating room procedureg 2,328,118 34.6 33.8−35.5 2.3 2.2−2.4
Operating room procedureh 1,977,291 29.4 28.7−30.1 2.2 2.1−2.3
a. Unweighted sample size.
b. Weighted percentage may not add-up exactly to 100.0%.
c. 95% confidence interval.
d. P-value for Pearson Chi-Square test.
e. May not be nationally representative because not all participating states collect race or ethnicity information.
f. Included “other race/ethnicity,” “Native American,” and “Asian or Pacific Islander.”
g. Had at least one minor diagnostic or minor therapeutic procedure (without any major diagnostic or major therapeutic procedure) during hospitalization.
h. Had at least one major diagnostic or major therapeutic procedure during hospitalization.
doi:10.1371/journal.pone.0123842.t001
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operating room procedures of any kind (36.0%) (Table 1). In 2011, the rate of VTE diagnosis
was 2.4% among hospitalizations of adults overall and varied significantly by age, sex, race or
ethnicity, total days of hospital stay, insurance status of primary expected payer, and status of
operating room procedure (P< 0.001). In addition, high rates of VTE diagnosis were observed
among subgroups of hospitalizations of adults who were 80 years of age or older (3.0%), were
male (2.9%), were Black (2.7%), had at least 7 total days of hospital stay (5.7%), had Medicare
insurance as primary expected payer (2.9%), and had no operating room procedures of any
kind (2.7%) (Table 1). Large percentages of the 1,039 hospitals in the sample were small bed
size (42.2%); urban non-teaching (43.6%); or private, nonprofit (58.1%) (Fig 1).
Measures of Fixed-Effect Association
The results of fixed-effect association based on three separate regression models are presented
in Table 2. When compared with the corresponding subgroups of hospitalizations of adults
who were 18−49 years of age, were female, were White, had less than 7 total days of stay, had
Medicaid insurance as primary expected payer, or had an operating room procedure,
Fig 1. Number and percentage distributions of hospitals (n = 1,039) by hospital characteristics, NIS, 2011.
doi:10.1371/journal.pone.0123842.g001
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Table 2. Adjusted odds ratios for VTE diagnosis among hospitalizations of US adults by multilevel determinants, NIS, 2011.
Multilevel determinantsa VTE diagnosis
Model 1b Model 2c Model 3d
ne ORf 95% CIg OR 95% CI OR 95% CI
INDIVIDUAL HOSPITALIZATION LEVEL 6,710,066
Age (years)
50−79 (vs 18−49) 3,210,405 1.50 1.45−1.56 1.38 1.34−1.42 1.38 1.34−1.42
 80 (vs 18−49) 1,193,718 1.55 1.51−1.60 1.32 1.27−1.36 1.32 1.27−1.36
Sex
Male (vs Female) 2,708,723 1.19 1.17−1.20 1.21 1.19−1.23 1.21 1.19−1.23
Race or ethnicity
Black (vs White) 929,079 1.19 1.17−1.22 1.16 1.14−1.18 1.16 1.13−1.18
Hispanic (vs White) 641,244 0.78 0.75−0.81 0.79 0.77−0.82 0.79 0.77−0.82
Otherh (vs White) 338,916 0.78 0.74−0.83 0.79 0.74−0.84 0.79 0.74−0.84
Not stated (vs White) 624,197 0.91 0.85−0.98 0.93 0.88−1.00 0.94 0.88−1.00
Total days of hospital stay
 7 days (vs < 7 days) 1,256,810 3.48 3.38−3.59 3.00 2.91−3.08 3.00 2.91−3.08
Primary expected payer
Medicare (vs Medicaid) 3,142,530 1.20 1.17−1.24 1.16 1.13−1.20 1.16 1.13−1.20
Private including HMO (vs Medicaid) 1,972,074 1.28 1.23−1.32 1.27 1.23−1.31 1.27 1.23−1.31
Self-pay or other payers (vs Medicaid) 592,083 1.15 1.11−1.20 1.21 1.16−1.26 1.21 1.16−1.26
Operating room procedure
Non-operating room procedurei (vs operating room procedurej) 2,328,118 1.02 0.99−1.06 0.97 0.93−1.00 0.97 0.93−1.00
No procedure of any kind (vs operating room procedure) 2,404,657 1.46 1.40−1.53 1.51 1.44−1.57 1.51 1.45−1.57
Acquired immune deficiency syndrome 15,934 − k − 1.33 1.22−1.45 1.33 1.22−1.45
Alcohol abuse 295,743 − − 0.69 0.66−0.72 0.69 0.66−0.72
Anemia (deficiency) 1,172,235 − − 1.26 1.24−1.28 1.26 1.24−1.28
Arthritis (rheumatoid)/collagen vascular diseases 179,371 − − 1.24 1.21−1.28 1.24 1.21−1.28
Chronic blood loss anemia 159,605 − − − g − − −
Congestive heart failure 564,645 − − 1.08 1.06−1.10 1.08 1.06−1.10
Chronic pulmonary disease 1,197,654 − − − − − −
Coagulopathy 308,968 − − 1.55 1.51−1.58 1.55 1.51−1.58
Depression 720,809 − − − − − −
Diabetes, uncomplicated 1,254,886 − − 0.85 0.83−0.86 0.85 0.83−0.86
Diabetes with chronic complications 301,405 − − − − − −
Drug abuse 270,125 − − − − − −
Hypertension (uncomplicated & complicated) 3,280,440 − − 1.06 1.04−1.08 1.06 1.04−1.07
Hypothyroidism 749,975 − − 0.96 0.94−0.98 0.96 0.94−0.98
Liver disease 189,225 − − 0.84 0.81−0.87 0.84 0.81−0.87
Lymphoma 51,298 − − 1.59 1.51−1.66 1.58 1.51−1.66
Fluid and electrolyte disorders 1,494,353 − − − − − −
Metastatic cancer 143,200 − − 2.91 2.81−3.00 2.91 2.81−3.00
Other neurological disorders 495,916 − − 1.11 1.09−1.13 1.11 1.09−1.13
Obesity 733,122 − − 1.39 1.36−1.42 1.39 1.36−1.42
Paralysis 160,997 − − 1.24 1.20−1.28 1.24 1.20−1.28
Peripheral vascular disorders 393,677 − − 0.83 0.81−0.85 0.83 0.81−0.85
Psychoses 305,283 − − 0.97 0.94−1.00 0.97 0.94−1.00
Pulmonary circulation disordersl 114,931 − − 2.06 1.98−2.13 2.06 1.98−2.13
(Continued)
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subgroups of hospitalizations of adults who were 50−79 years of age (aOR = 1.50; 95% CI: 1.45
−1.56), were 80 years of age or older (aOR = 1.55; 95% CI: 1.51−1.60), were male (aOR = 1.19;
95% CI: 1.17−1.20), were Black (aOR = 1.19; 95% CI: 1.17−1.22), had at least 7 total days of
hospital stay (aOR = 3.48; 95% CI: 3.38−3.59), had Medicare insurance (aOR = 1.20; 95% CI:
1.17−1.24), had private including HMO insurance (aOR = 1.28; 95% CI: 1.23−1.32), had self-
pay or other payers insurance (aOR = 1.15; 95% CI: 1.11−1.20), or had no procedure of any
Table 2. (Continued)
Multilevel determinantsa VTE diagnosis
Model 1b Model 2c Model 3d
ne ORf 95% CIg OR 95% CI OR 95% CI
Renal failure 786,447 − − 1.04 1.02−1.06 1.04 1.02−1.06
Solid tumor without metastasis 132,594 − − 2.23 2.17−2.30 2.23 2.17−2.30
Peptic ulcer disease excluding bleeding 2,140 − − − − − −
Valvular disease 237,468 − − − − − −
Weight loss 322,748 − − 1.41 1.38−1.44 1.41 1.38−1.44
HOSPITAL LEVEL
Bed size
Medium (vs Small) 1,600,501 − − − − − −
Large (vs Small) 4,275,498 − − − − − −
Location and teaching status
Urban non-teaching (vs Rural) 2,843,551 − − − − 1.14 1.07−1.21
Urban teaching (vs Rural) 3,107,244 − − − − 1.15 1.08−1.23
Ownership
Private, non-profit (vs Gov, non-federal) 5,038,418 − − − − − −
Private, investor own (vs Gov, non-federal) 965,283 − − − − − −
Variance component Model 0m Model 1 Model 2 Model 3
Intercept variance 0.261* 0.168* 0.136* 0.133*
Intraclass correlation coefficient (%) 7.4 4.9 4.0 3.9
a. Determinants are in bold.
b. Generalized linear mixed model that adjusted for age, sex, race or ethnicity, total days of hospital stay, primary expected payer, and operating
room procedure.
c. Generalized linear mixed model that adjusted for all determinants in model 1 and significant preexisting comorbid conditions (i.e., acquired immune
deficiency syndrome, alcohol abuse, anemia, arthritis, congestive heart failure, coagulopathy, diabetes, uncomplicated, hypertension, hypothyroidism, liver
disease, lymphoma, metastatic cancer, other neurological disorders, obesity, paralysis, peripheral vascular disorders, psychoses, pulmonary circulation
disorders, renal failure, solid tumor without metastasis, and weight loss).
d. Generalized linear mixed model that adjusted for all determinants in model 2 and hospital location and teaching status.
e. Unweighted sample sizes for non-referent subgroups are shown. Referent groups were hospitalizations of adults without corresponding conditions
(referent subgroups n = 6,710,066—n for non-referent subgroups).
f. Odds ratio.
g. Confidence interval.
h. Included “other race/ethnicity,” “Native American,” and “Asian or Pacific Islander.”
i. Had at least one minor diagnostic or minor therapeutic procedure (without any major diagnostic or major therapeutic procedure) during hospitalization.
j. Had at least one major diagnostic or major therapeutic procedure during hospitalization.
k. Eliminated variable not in the final model.
l. Hospitalizations with PE and without other diseases in the category were classified as having negative status for the disorder.
m. Unconditional, empty model with no covariate.
*P < 0.001.
doi:10.1371/journal.pone.0123842.t002
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kind (aOR = 1.46; 95% CI: 1.40−1.53) were each positively and independently associated with a
VTE diagnosis (model 1). By simultaneously adjusting for the significant preexisting comorbid
conditions (P< 0.05) and determinants presented in model 1, each subgroup of hospitaliza-
tions of adults with acquired immune deficiency syndrome (AIDS), anemia, arthritis, conges-
tive heart failure, coagulopathy, hypertension, lymphoma, metastatic cancer, other
neurological disorders, obesity, paralysis, pulmonary circulation disorders, renal failure, solid
tumor without metastasis, or weight loss was associated positively and independently with an
increased likelihood (aORs ranged from 1.04 [95% CI: 1.02−1.06] to 2.91 [95% CI: 2.81−3.00])
of VTE diagnosis, compared with those without any of the corresponding 15 preexisting co-
morbid conditions (model 2). Upon further adjusting for hospital level determinant (i.e., hospi-
tal location and teaching status) (P< 0.05), hospitalizations of adults who were treated in
“urban non-teaching” or “urban teaching” hospitals were associated with 1.14 (95% CI:
Fig 2. Percentage distribution of hospitalizations of US adults and odds ratios for VTE diagnosis by number of selected preexisting comorbid
conditions, NIS, 2011.
doi:10.1371/journal.pone.0123842.g002
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1.07−1.21) and 1.15 (95% CI: 1.08−1.23) times increased likelihoods of VTE diagnosis, respec-
tively, when compared with a subgroup of hospitalizations of adults who were treated in rural
hospitals (model 3). The patterns and strengths of association of demographic characteristics
and clinical and insurance status with VTE diagnosis did not change appreciably in models 2
and 3. Fig 2 illustrates that approximately two of three hospitalizations of adults had at least 1
of the 15 preexisting comorbid conditions that were associated with a VTE diagnosis, and the
cumulative number of these diseases corresponded to a 1.9- to 5.5-fold increased likelihood of
VTE diagnosis (P< 0.001 for linear trend).
Measures of Random-Effect Variation
The estimate of intercept variance suggested an appreciable variation in probability of VTE di-
agnosis occurred between hospitals. The value of ICC indicated that approximately 7.4% of the
total variation or differences in probability of VTE diagnosis occurred between hospitals and
might have been attributable to potential contextual factors of the hospitals (model 0).
Discussion
By analyzing a large sample of 6.7 million hospitalizations of adults nested within 1,039 hospi-
tals in the United States from the 2011 NIS, our study expanded existing research through eval-
uation of both compositional effects from individual hospitalizations and contextual effects
from hospitals on VTE diagnosis in the United States. The simultaneous effects of multilevel
determinants of VTE encompassing demographic, clinical and insurance status, preexisting co-
morbid conditions, and hospital characteristics have not been characterized and reported in
the past. Our results showed that, of all hospitalizations of US adults, 64.4% had at least 1 and
35.6% had at least 2 of the 15 preexisting comorbid conditions (AIDS, anemia, arthritis,
congestive heart failure, coagulopathy, hypertension, lymphoma, metastatic cancer, other neu-
rological disorders, obesity, paralysis, pulmonary circulation disorders, renal failure, solid
tumor without metastasis, and weight loss). When compared with hospitalizations of adults
without the corresponding conditions, the presence of these preexisting comorbid conditions
showed a 4%−191% increased likelihood of a VTE diagnosis; the presence of 2 or more of such
conditions was associated a 190%−450% increased likelihood of a VTE diagnosis. Moreover,
approximately a 7.4% variation in VTE diagnosis could have been attributable to contextual
factors of hospitals. For example, we found that hospitalizations of adults at urban hospitals
had about a 14%−15% increased likelihood of a VTE diagnosis relative to those at rural hospi-
tals, regardless of the hospital’s teaching status.
Our findings were consistent with existing evidence showing that factors such as having an
advanced age, being male (e.g., for recurrent VTE), being Black, and having had a prolonged
hospital stay were associated with an increased risk for VTE [26, 27]. We observed an increased
likelihood of a VTE diagnosis when comparing hospitalizations of adults who had no proce-
dure of any kind with those who had an operative room procedure. Despite the greater risk for
VTE among surgical patients, previous research showed that medical patients were less likely
to receive VTE prophylaxis and had more episodes of VTE and higher rates of pulmonary em-
bolism and death [7, 28–31]. We postulated that hospitalizations of adults with no procedure
of any kind included mostly medical patients. Differences in the clinical practice of VTE pro-
phylaxis among clinicians in healthcare settings for patients with various health conditions
may affect VTE risk. In addition, some preexisting comorbid conditions (e.g., rheumatoid ar-
thritis, congestive heart failure, pulmonary circulation disorders, obesity, hypertension, and
cancer with or without metastasis) have been identified as risk factors for VTE in previous re-
search [32–36]. Diseases or conditions that perhaps had attracted less prominent attention for
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their roles in VTE development included iron deficiency anemia, AIDS or human immunode-
ficiency virus infection, coagulopathy, neurological disorders, paralysis, renal failure, and
weight loss [37–44]. In general, the coexistence of two or more conditions can affect other dis-
ease or health outcome through the etiological mechanisms of direct causation, associated risk
factors, heterogeneity, and independence [45]. The use of our 15 identified preexisting comor-
bid conditions for VTE risk assessment and prediction might be explored and validated further
in future studies.
Hospitals in which people receive care can influence health outcomes via availability and ac-
cessibility of health services, as well as prevailing practices and attitudes towards compliance
with clinical guidelines and adherence to therapies. The exact reason for an elevated likelihood
of VTE diagnosis in hospitalizations at urban hospitals compared with those at rural hospitals
was unclear. It could be attributable to the increased availability, accessibility, and utilization of
diagnostic services including computed tomography and magnetic resonance imaging, as well
as concentration of patients with more complicated conditions. The evidence and effects of sig-
nificant variation in VTE diagnosis between hospitals were consistent with typical neighbor-
hood effects on health outcomes [46]. Earlier studies have suggested that hospital ownership
and teaching status were not associated consistently with patient outcomes even though differ-
ences in disease-specific populations may exist [47, 48]. When comparing hospitalizations with
Medicaid insurance as the primary expected payer, we observed an increased likelihood of
VTE diagnosis among hospitalizations of adults with Medicare; private insurance, including an
HMO; or self-pay insurance. Additional research is needed to discern the effect of a higher
level structure defined by hospitals or alternative contextual boundaries (e.g., type of insurance
payer, team and institutional support, practice, policy, and education) that might shape the en-
vironments and processes of healthcare services.
Our results were based on a cross-sectional study which is not designed to establish a cause-
effect relationship. The analytical units of the study were hospitalizations and hospitals. The
rate of VTE diagnosis among hospitalizations did not necessarily reflect rates per patients, as
individual patients could have had multiple hospitalizations. Because the NIS did not identify
multiple hospitalizations for individual patients, patient-level of analysis could not be per-
formed. In addition, our study had several other limitations. First, we could not determine if a
VTE event had been present on admission or occurred during a hospital stay. Second, 9.2%
hospitalizations of adults had missing information on race which might lead to potential mis-
classification; therefore, caution should be excised when interpreting results related to race.
Third, some preexisting comorbid conditions (e.g., obesity and weight loss) were not defined
uniformly and measured objectively. The accuracy of ICD-9-CM diagnostic codes can be affect-
ed by physician documentation; the availability, accessibility, and utilization of diagnostic tests;
and reimbursement guidelines [49]. Fourth, the length of hospital stay could be a cause or an
effect of having VTE, since patients who develop VTE prior to discharge might also have a lon-
ger duration of hospital stay due to the need to treat the VTE. As such, the total days of hospital
stay was not necessarily an independent variable for predicting VTE risk in this study. Never-
theless, we did not identify appreciable differences in the associations between having a VTE
diagnosis and other covariates upon removing the variable of total days of hospital stay from
the regression models. Finally, although we evaluated several hospital characteristics (such as
bed size, location and teaching status, and ownership), the variation in VTE diagnosis may
have arisen from alternative higher level structures and other contextual factors such as avail-
ability and accessibility of advanced equipment and services that were not evaluated [46, 50].
The results from this study have several important clinical and public health implications.
To date, a number of evidence-based clinical practice guidelines for VTE prevention using
pharmacologic agents and mechanical devices have been developed and are available for
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various patient populations [12, 13]. Given that more than two-thirds of hospitalizations of
adults might have been associated with one or more preexisting comorbid conditions that
might predispose them to a heightened risk for VTE and that the concerns of suboptimal VTE
risk assessment and prophylaxis for patients, our findings signify the importance of adherence
to VTE prevention guidelines. Health care practitioners need to be informed of various risk fac-
tors for VTE risk among hospitalized patients in order to perform appropriate risk assessments
to identify and provide counseling to those who might benefit from VTE prophylaxis. Our re-
sults also might increase the awareness of VTE among patients and healthcare practitioners
and thereby contribute to appropriate decisions for prophylaxis. Patients should keep their
doctors informed about their medical history and health conditions, discuss VTE prevention
with their doctors during their hospital stay, and adhere to prescribed therapies. Finally, the ef-
fects and complexity of multilevel risk factors for VTE illustrate the need for comprehensive
public health approaches and evidence-based research to identify multidisciplinary strategies
that integrate science, clinical practice, and institutional support to prevent VTE among
hospitalized patients.
In summary, the results of our study indicate that the presence of certain comorbidities and
hospital contextual factors is associated with significantly elevated likelihood of VTE diagnosis
among hospitalizations of adults. The findings of this study underscore the importance of clini-
cal risk assessment and adherence to evidence-based clinical practice guidelines in preventing
VTE, as well as the need to evaluate potential contextual factors that might modify the risk of
VTE among hospitalized patients.
Acknowledgments
The authors of this study sincerely thank the coordinators of the Healthcare Cost and Utiliza-
tion Project for all participating states, and the Agency for Healthcare Research and Quality,
Rockville, Maryland, for making the data available.Disclaimer: The findings and conclusions
in this report are those of the authors and do not necessarily represent the official position of
the Centers for Disease Control and Prevention.
Author Contributions
Conceived and designed the experiments: JT AMG. Performed the experiments: JT AMG
MGB SDG HRY LCR. Analyzed the data: JT. Contributed reagents/materials/analysis tools: JT
AMGMGB SDG HRY LCR. Wrote the paper: JT. Critical revision of the paper for important
intellectual content: JT AMGMGB SDG HRY LCR. Administrative, technical, material sup-
port, and study supervision: AMG LCR.
References
1. DHHS. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embo-
lism. Office of the Surgeon General. U.S. Department of Health & Human Services. Washington, DC.
Availabe URL (accessed August 8, 2011): http://www.surgeongeneral.gov/topics/deepvein/
calltoaction/call-to-action-on-dvt-2008.pdf. 2008.
2. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. Venous thromboembolism
prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Preven-
tion Registry on Venous Thromboembolism. Chest. 2007 Sep; 132(3):936–45. PMID: 17573514
3. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review.
Journal of medical economics. 2011; 14(1):65–74. doi: 10.3111/13696998.2010.546465 PMID:
21222564
4. Tsai J, Abe K, Boulet SL, Beckman MG, Hooper WC, Grant AM. Predictive accuracy of 29-comorbidity
index for in-hospital deaths in US adult hospitalizations with a diagnosis of venous thromboembolism.
PLOS ONE. 2013; 8(7):e70061. doi: 10.1371/journal.pone.0070061 PMID: 23922902
Multilevel Determinants of VTE
PLOSONE | DOI:10.1371/journal.pone.0123842 April 16, 2015 12 / 15
5. Tsai J, Grant AM, Soucie JM, Helwig A, Yusuf HR, Boulet SL, et al. Clustering Patterns of Comorbidities
Associated with In-Hospital Death in Hospitalizations of US Adults with Venous Thromboembolism. In-
ternational journal of medical sciences. 2013; 10(10):1352–60. doi: 10.7150/ijms.6714 PMID:
23983596
6. Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, et al. Incidence of venous
thromboembolism in hospitalized patients vs community residents. Mayo Clinic proceedings Mayo Clin-
ic. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. 2001 Nov; 76(11):1102–10. PMID:
11702898
7. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient
setting. Arch Intern Med. [Research Support, N.I.H., Extramural]. 2007 Jul 23; 167(14):1471–5. PMID:
17646600
8. White RH. Identifying risk factors for venous thromboembolism. Circulation. [Comment Editorial]. 2012
May 1; 125(17):2051–3. doi: 10.1161/CIRCULATIONAHA.112.102814 PMID: 22474263
9. Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and throm-
bosis: Virchow's triad revisited. Anesthesia and analgesia. 2012 Feb; 114(2):275–85. doi: 10.1213/
ANE.0b013e31823a088c PMID: 22104070
10. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann
Intern Med. 2009 Aug 4; 151(3):180–90. PMID: 19581633
11. Maynard GA, Stein J. Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective
Quality Improvement. Prepared by the Society of Hospital Medicine. AHRQ Publication No. 08–0075.
Rockville, MD. AHRQ. 2010 August.
12. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American College of Chest Physi-
cians Antithrombotic T, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombo-
sis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
2012 Feb; 141(2 Suppl):7S–47S. doi: 10.1378/chest.1412S3 PMID: 22315257
13. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P, Clinical Guidelines Committee of the Ameri-
can College of P. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice
guideline from the American College of Physicians. Ann Intern Med. 2011 Nov 1; 155(9):625–32. doi:
10.7326/0003-4819-155-9-201111010-00011 PMID: 22041951
14. Vogeli C, Kang R, LandrumM, HasnainWynia R, Weissman J. Quality of care provided to individual pa-
tients in US hospitals: results from an analysis of national Hospital Quality Alliance data. Medical care.
2009; 47(5):591–9. doi: 10.1097/MLR.0b013e31819432cd PMID: 19365292
15. Foster D, Zrull L, Chenoweth J. Hospital Performance Differences by Ownership. Research Brief. 100
Top Hospitals: Study Overview, 20th Edition. Ann Arbor, MI. Truven Health Analytics. 2013.
16. Houchens R, Chu B, Steiner C. Hierarchical modeling using HCUP data. HCUPmethods series report
# 2007–01 Online. January 10, 2007. U.S. Agency for Healthcare Research and Quality. Available:
http://www.hcup-us.ahrq.gov/reports/methods.jsp. Last accessed: June 14, 2013. 2007.
17. Huseynova K, XiongW, Ray JG, Ahmed N, Nathens AB. Venous Thromboembolism as a Marker of
Quality of Care in Trauma. Journal of the American College of Surgeons. 2009 4//; 208(4):547–52.e1.
doi: 10.1016/j.jamcollsurg.2009.01.002 PMID: 19476788
18. AHRQ. Overview of the Nationwide Inpatient Sample (NIS). Agency for Healthcare Research and
Quality (AHRQ). Rockville, MD. URL accessed on 8/2/2013: http://www.hcup-us.ahrq.gov/
nisoverview.jsp. 2013.
19. AHRQ. Introduction to the HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization
Project (HCUP). 2011. Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. URL ac-
cessed on 8/2/2013: http://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2011.pdf. 2013.
PMID: 22514803
20. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data.
Med Care. 1998 Jan; 36(1):8–27. PMID: 9431328
21. AHRQ. Comorbidity Software, Version 3.7. Agency for Healthcare Research and Quality (AHRQ).
Rockville, MD. URL accessed on 3/22/2012: http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/
comorbidity.jsp. 2012.
22. AHRQ. Procedure Classes 2012. Agency for Healthcare Research and Quality (AHRQ). Rockville,
MD. URL accessed on 7/12/2012: http://www.hcup-us.ahrq.gov/toolssoftware/procedure/procedure.
jsp. 2012.
23. AHRQ. Major operating room procedure indicator. Agency for Healthcare Research and Quality
(AHRQ). Rockville, MD. URL accessed on 7/12/2012: http://www.hcup-us.ahrq.gov/db/vars/orproc/
nisnote.jsp. 2012.
Multilevel Determinants of VTE
PLOSONE | DOI:10.1371/journal.pone.0123842 April 16, 2015 13 / 15
24. Snijders TAB, Bosker R. Multilevel Analysis: An Introduction to Basic and AdvancedMultilevel Model-
ing. Second ed: SAGE Publications Ltd; 2011.
25. Carle AC. Fitting multilevel models in complex survey data with design weights: Recommendations.
BMCMed Res Methodol. 2009; 9:49. doi: 10.1186/1471-2288-9-49 PMID: 19602263
26. Keenan CR, White RH. The effects of race/ethnicity and sex on the risk of venous thromboembolism.
Current opinion in pulmonary medicine. 2007 Sep; 13(5):377–83. PMID: 17940480
27. Yusuf HR, Reyes N, Zhang QC, Okoroh EM, Siddiqi AE, Tsai J. Hospitalizations of Adults > = 60 Years
of AgeWith Venous Thromboembolism. Clin Appl Thromb Hemost. 2013 Jun 27.
28. Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalized medical patients who
developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolismmore fre-
quent. Chest. 2007 Aug; 132(2):554–61. PMID: 17573518
29. Kaboli PJ, Brenner A, Dunn AS. Prevention of venous thromboembolism in medical and surgical pa-
tients. Cleveland Clinic journal of medicine. 2005 Apr; 72 Suppl 1:S7–13. PMID: 15853174
30. Streiff MB, Lau BD. Thromboprophylaxis in nonsurgical patients. Hematology Am Soc Hematol Educ
Program. 2012; 2012:631–7. doi: 10.1182/asheducation-2012.1.631 PMID: 23233645
31. Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ, et al. Assessment of venous throm-
boembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005
Oct; 94(4):750–9. PMID: 16270626
32. Dean SM, AbrahamW. Venous thromboembolic disease in congestive heart failure. Congestive heart
failure. 2010 Jul-Aug; 16(4):164–9. doi: 10.1111/j.1751-7133.2010.00148.x PMID: 20662869
33. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and bene-
fits of thromboprophylaxis. Cancer. 2011 Apr 1; 117(7):1334–49. doi: 10.1002/cncr.25714 PMID:
21425133
34. Lopes AA. Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hyper-
tension. Cardiovascular & hematological agents in medicinal chemistry. 2006 Jan; 4(1):53–9.
35. AgenoW, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous
thromboembolism: a meta-analysis. Circulation. 2008 Jan 1; 117(1):93–102. PMID: 18086925
36. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheu-
matoid arthritis. Arthritis care & research. 2013 Oct; 65(10):1600–7.
37. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, et al. Chronic dialysis patients have
high risk for pulmonary embolism. American journal of kidney diseases: the official journal of the Nation-
al Kidney Foundation. 2002 May; 39(5):1011–7. PMID: 11979344
38. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep
vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med.
2000 Mar 27; 160(6):809–15. PMID: 10737280
39. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous
thromboembolism in hospitalized patients with chronic liver disease. Chest. 2010 May; 137(5):1145–9.
doi: 10.1378/chest.09-2177 PMID: 20040609
40. Bibas M, Biava G, Antinori A. HIV-Associated Venous Thromboembolism. Mediterranean journal of he-
matology and infectious diseases. 2011; 3(1):e2011030. doi: 10.4084/MJHID.2011.030 PMID:
21869916
41. Franchini M, Targher G, MontagnanaM, Lippi G. Iron and thrombosis. Annals of hematology. 2008
Mar; 87(3):167–73. PMID: 18066546
42. Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with
the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the
General Practice Research Database. BJOG. 2009 Jan; 116(1):91–7. doi: 10.1111/j.1471-0528.2008.
01926.x PMID: 19016686
43. Wattanakit K, CushmanM, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease in-
creases risk for venous thromboembolism. Journal of the American Society of Nephrology: JASN. 2008
Jan; 19(1):135–40. PMID: 18032796
44. Folsom AR, Boland LL, CushmanM, Heckbert SR, RosamondWD,Walston JD. Frailty and risk of ve-
nous thromboembolism in older adults. The journals of gerontology Series A, Biological sciences and
medical sciences. 2007 Jan; 62(1):79–82. PMID: 17301042
45. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for un-
derstanding health and health services. Annals of family medicine. [Research Support, Non-U.S. Gov't
Review]. 2009 Jul-Aug; 7(4):357–63. doi: 10.1370/afm.983 PMID: 19597174
46. Pickett KE, Pearl M. Multilevel analyses of neighbourhood socioeconomic context and health out-
comes: a critical review. J Epidemiol Community Health. 2001 Feb; 55(2):111–22. PMID: 11154250
Multilevel Determinants of VTE
PLOSONE | DOI:10.1371/journal.pone.0123842 April 16, 2015 14 / 15
47. Papanikolaou PN, Christidi GD, Ioannidis JP. Patient outcomes with teaching versus nonteaching
healthcare: a systematic review. PLoSMed. 2006 Sep; 3(9):e341. PMID: 16968119
48. Thornlow D, Stukenborg G. The association between hospital characteristics and rates of preventable
complications and adverse events. Medical care. 2006; 44(3):265–9. PMID: 16501398
49. Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. JAMA. [Comment
Editorial]. 2012 Apr 4; 307(13):1433–5. doi: 10.1001/jama.2012.404 PMID: 22474208
50. Duncan C, Jones K, Moon G. Context, composition and heterogeneity: using multilevel models in
health research. Soc Sci Med. 1998 Jan; 46(1):97–117. PMID: 9464672
Multilevel Determinants of VTE
PLOSONE | DOI:10.1371/journal.pone.0123842 April 16, 2015 15 / 15
